Continued rapid growth in 68Ga applications: update 2013 to June 2014

The worldwide utilization of Ga-68-radionuclide for the fundamental research and clinical applications is growing exponentially. A broad range of Ga-68-based imaging agents has been explored during recent years. The development of new clinically useful agents is encouraged by many factors; for example, increasing role of positron emission tomography (PET) in nuclear medicine, discovery of new biomarkers, accessibility of Ga-68, and establishment of PET radiopharmaceutical regulation and legislation. The focus of this review resides on the reports regarding Ga-68-related research and applications published during 2013 to June 2014.